French Pharma Groups Face Traumatic Blows

When French authorities stopped reimbursing Multaq, a treatment for irregular heartbeat, late last year, it was more than just a blow to the country’s flagship pharmaceutical group. It signaled that the pressure on the French industry was more intense than in many other European states.
Financial Times